| Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing L Riva, S Yuan, X Yin, L Martin-Sancho, N Matsunaga, L Pache, ... Nature 586 (7827), 113-119, 2020 | 727 | 2020 |
| SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling L Miorin, T Kehrer, MT Sanchez-Aparicio, K Zhang, P Cohen, RS Patel, ... Proceedings of the National Academy of Sciences 117 (45), 28344-28354, 2020 | 473 | 2020 |
| SARS-CoV-2 spike E484K mutation reduces antibody neutralisation S Jangra, C Ye, R Rathnasinghe, D Stadlbauer, H Alshammary, ... The Lancet Microbe 2 (7), e283-e284, 2021 | 397 | 2021 |
| Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A KM White, R Rosales, S Yildiz, T Kehrer, L Miorin, E Moreno, S Jangra, ... Science 371 (6532), 926-931, 2021 | 297 | 2021 |
| Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection R Rathnasinghe, S Strohmeier, F Amanat, VL Gillespie, F Krammer, ... Emerging microbes & infections 9 (1), 2433-2445, 2020 | 173 | 2020 |
| Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2 TA Tummino, VV Rezelj, B Fischer, A Fischer, MJ O’meara, B Monel, ... Science 373 (6554), 541-547, 2021 | 162 | 2021 |
| Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission A Escalera, AS Gonzalez-Reiche, S Aslam, I Mena, M Laporte, RL Pearl, ... Cell host & microbe 30 (3), 373-387. e7, 2022 | 145 | 2022 |
| The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. S Jangra, C Ye, R Rathnasinghe, D Stadlbauer, F Krammer, V Simon, ... MedRxiv, 2021 | 137 | 2021 |
| The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera R Rathnasinghe, S Jangra, A Cupic, C Martínez-Romero, LCF Mulder, ... MedRxiv, 2021 | 113 | 2021 |
| Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection D Kaul, R Rathnasinghe, M Ferres, GS Tan, A Barrera, BE Pickett, ... Nature communications 11 (1), 2537, 2020 | 93 | 2020 |
| TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation JSY Ho, BWY Mok, L Campisi, T Jordan, S Yildiz, S Parameswaran, ... Cell 184 (10), 2618-2632. e17, 2021 | 83 | 2021 |
| A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses W Sun, Y Liu, F Amanat, I González-Domínguez, S McCroskery, ... Nature communications 12 (1), 6197, 2021 | 61 | 2021 |
| Sterilizing immunity against SARS‐CoV‐2 infection in mice by a single‐shot and lipid amphiphile imidazoquinoline TLR7/8 agonist‐adjuvanted recombinant spike protein vaccine S Jangra, J De Vrieze, A Choi, R Rathnasinghe, G Laghlali, A Uvyn, ... Angewandte Chemie International Edition 60 (17), 9467-9473, 2021 | 50 | 2021 |
| Limited extent and consequences of pancreatic SARS-CoV-2 infection V van der Heide, S Jangra, P Cohen, R Rathnasinghe, S Aslam, T Aydillo, ... Cell Reports 38 (11), 2022 | 49 | 2022 |
| Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model F Amanat, S Strohmeier, R Rathnasinghe, M Schotsaert, L Coughlan, ... MBio 12 (2), 10.1128/mbio. 02648-20, 2021 | 46 | 2021 |
| COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models P Maisonnasse, Y Aldon, A Marc, R Marlin, N Dereuddre-Bosquet, ... Nature communications 12 (1), 6097, 2021 | 43 | 2021 |
| SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2: e283–e284 S Jangra, C Ye, R Rathnasinghe, D Stadlbauer, F Krammer, V Simon, ... | 40 | 2021 |
| The virucidal effects of 405 nm visible light on SARS-CoV-2 and influenza A virus R Rathnasinghe, S Jangra, L Miorin, M Schotsaert, C Yahnke, ... Scientific Reports 11 (1), 19470, 2021 | 38 | 2021 |
| Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis T Kehrer, A Cupic, C Ye, S Yildiz, M Bouhaddou, NA Crossland, ... Cell Host & Microbe 31 (10), 1668-1684. e12, 2023 | 27 | 2023 |
| Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultraviolet C (UVC) irradiation device R Rathnasinghe, RF Karlicek Jr, M Schotsaert, M Koffas, BL Arduini, ... Scientific Reports 11 (1), 19970, 2021 | 26 | 2021 |
